- GT Biopharma, Inc.’s (GTBP) stock has more than quintupled since it began providing data from a Phase 1 trial evaluating its only clinical asset (GTB-3550) in the treatment of AML.
- Bone marrow blast reductions were observed in three of five patients in the higher dose cohorts with no dose-limiting toxicity observed.
- With a potential off-the-shelf (i.e. cost-effective) therapy for rescuing patients’ own natural killer cells without removing them, GT merited a deeper dive.
- A full investment analysis follows in the paragraphs below.
For further details see:
Getting To Know GT Biopharma